R&D
Focus Areas Pipeline
PluraStem™ ImmuStem™ MesoStem™ AlloGraf™ GlucoStem™ MorphoGel™ FibroStem™ Neurox™ OsteoStem™ Intellectual Property PublicationsMesoStem™
Using its universal human embryonic stem cell (ESC) line, PluraStem™, Escape is creating an off-the-shelf MSC that can be transplanted into patients of any HLA type without the need for lifelong immunosuppression. Escape's MSC product, MesoStem™, holds the key advantage of stable, long-term suppression of the autoimmune destruction process responsible for type I diabetes progression. Other advantages over unmodified MSC products include more favorable dosing schedules and predictable clinical efficacy. A partial list of the disease indications potentially treatable with Escape's MesoStem™ product is shown below:
| Clinical Indications for MesoStem™ |
|---|
| Type I diabetes (onset/progression) |
| Psoriasis |
| Systemic Lupus Erythematosus |
| Inflammatory Bowel Disease |
| Rheumatoid Arthritis |
| Graft-Versus-Host Disease |
